바이오인

 

 

 

In recent years, international research on regenerative medicine and stem cells has yielded some promising results and even greater expectations in society. Europe is currently witnessing developments and debates that will impact regulation and
public funding of stem cell research and innovation for years to come. In the light of these s and the international collaborations emerging, key questions arise: How do current policy and regulatory frameworks differ across Europe? Is there a need for pan-European alignment of regulations and funds? Should the European Union continue to sponsor human stem cell research, particularly under Horizon 2020?

This European Science Foundation (ESF) report presents a comparative overview of the legislative framework on human stem cell research across 30 countries, a brief compilation of ESF collaborative research funding opportunities, and a collection
of relevant European outputs in this field. Overall, countries’ positions on human stem cell research can be grouped in five broad categories: very permissive, permissive with restrictions, restrictive by default, very restrictive, and unlegislated. Sixty-three percent of the countries studied fall into the first two categories. Legal sources of human embryonic stem cells (hESCs) vary across Europe, with very few countries authorising the creation of embryos exclusively for research purposes. Most nations only allow for the derivation of hESCs from surplus in vitro fertilisation (IVF) embryos. Few countries ban the derivation of these cells altogether, and yet some permit cell line imports under strict conditions. In addition, the brief ion of promising results in terms of scientific production and clinical trials highlights the achievements of a vibrant community
of scientists and innovators.

The evidence contained in this report suggests that Europe has a substantial track record and an unprecedented opportunity to leverage on the benefits of the investments and efforts made to date. For this to happen, sustained public endorsement and
funding need to continue, so that further research is carried out and public-private partnerships develop to bring safe and innovative therapies to the market for the potential benefit of millions of patients worldwide. This report may help to inform future
policy and funding decisions across Europe and thus contribute to ensuring this continent’s scientific leadership, social welfare and economic growth.

 

 

.....(계속)